Metastatic Breast Cancer - Pipeline Review, H1 2015


#316364

866pages

Global Markets Direct

$ 2000

In Stock

Metastatic Breast Cancer - Pipeline Review, H1 2015

Summary

Global Markets Directs, Metastatic Breast Cancer - Pipeline Review, H1 2015, provides an overview of the Metastatic Breast Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
Introduction 7
Metastatic Breast Cancer Overview 8
Therapeutics Development 9
Metastatic Breast Cancer - Therapeutics under Development by Companies 11
Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes 21
Metastatic Breast Cancer - Pipeline Products Glance 23
Metastatic Breast Cancer - Products under Development by Companies 27
Metastatic Breast Cancer - Products under Investigation by Universities/Institutes 41
Metastatic Breast Cancer - Companies Involved in Therapeutics Development 43
Metastatic Breast Cancer - Therapeutics Assessment 155
Drug Profiles 180
Metastatic Breast Cancer - Recent Pipeline Updates 581
Metastatic Breast Cancer - Dormant Projects 817
Metastatic Breast Cancer - Discontinued Products 828
Metastatic Breast Cancer - Product Development Milestones 833
Appendix 843

List of Tables
Number of Products under Development for Metastatic Breast Cancer, H1 2015 31
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2015 32
Number of Products under Development by Companies, H1 2015 34
Number of Products under Development by Companies, H1 2015 (Contd..1) 35
Number of Products under Development by Companies, H1 2015 (Contd..2) 36
Number of Products under Development by Companies, H1 2015 (Contd..3) 37
Number of Products under Development by Companies, H1 2015 (Contd..4) 38
Number of Products under Development by Companies, H1 2015 (Contd..5) 39
Number of Products under Development by Companies, H1 2015 (Contd..6) 40
Number of Products under Development by Companies, H1 2015 (Contd..7) 41
Number of Products under Development by Companies, H1 2015 (Contd..8) 42
Number of Products under Investigation by Universities/Institutes, H1 2015 44
Comparative Analysis by Late Stage Development, H1 2015 45
Comparative Analysis by Clinical Stage Development, H1 2015 46
Comparative Analysis by Early Stage Development, H1 2015 47
Comparative Analysis by Unknown Stage Development, H1 2015 48
Products under Development by Companies, H1 2015 49
Products under Development by Companies, H1 2015 (Contd..1) 50
Products under Development by Companies, H1 2015 (Contd..2) 51
Products under Development by Companies, H1 2015 (Contd..3) 52
Products under Development by Companies, H1 2015 (Contd..4) 53
Products under Development by Companies, H1 2015 (Contd..5) 54
Products under Development by Companies, H1 2015 (Contd..6) 55
Products under Development by Companies, H1 2015 (Contd..7) 56
Products under Development by Companies, H1 2015 (Contd..8) 57
Products under Development by Companies, H1 2015 (Contd..9) 58
Products under Development by Companies, H1 2015 (Contd..10) 59
Products under Development by Companies, H1 2015 (Contd..11) 60
Products under Development by Companies, H1 2015 (Contd..12) 61
Products under Development by Companies, H1 2015 (Contd..13) 62
Products under Investigation by Universities/Institutes, H1 2015 63
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 64
Metastatic Breast Cancer - Pipeline by AbbVie Inc., H1 2015 65
Metastatic Breast Cancer - Pipeline by Advaxis, Inc., H1 2015 66
Metastatic Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 67
Metastatic Breast Cancer - Pipeline by AlphaVax, Inc., H1 2015 68
Metastatic Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2015 69
Metastatic Breast Cancer - Pipeline by Amgen Inc., H1 2015 70
Metastatic Breast Cancer - Pipeline by AngioGenex, Inc., H1 2015 71
Metastatic Breast Cancer - Pipeline by Aphios Corporation, H1 2015 72
Metastatic Breast Cancer - Pipeline by arGEN-X BV, H1 2015 73
Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 74
Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H1 2015 75
Metastatic Breast Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 76
Metastatic Breast Cancer - Pipeline by Bavarian Nordic A/S, H1 2015 77
Metastatic Breast Cancer - Pipeline by Bayer AG, H1 2015 78
Metastatic Breast Cancer - Pipeline by BIOCAD, H1 2015 79
Metastatic Breast Cancer - Pipeline by Biocon Limited, H1 2015 80
Metastatic Breast Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015 81
Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 82
Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 83
Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2015 84
Metastatic Breast Cancer - Pipeline by Celgene Corporation, H1 2015 85
Metastatic Breast Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 86
Metastatic Breast Cancer - Pipeline by Celltrion, Inc., H1 2015 87
Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015 88
Metastatic Breast Cancer - Pipeline by Curadis GmbH, H1 2015 89
Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 90
Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 91
Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici S.p.A., H1 2015 92
Metastatic Breast Cancer - Pipeline by Eisai Co., Ltd., H1 2015 93
Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H1 2015 94
Metastatic Breast Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 95
Metastatic Breast Cancer - Pipeline by Etubics Corporation, H1 2015 96
Metastatic Breast Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2015 97
Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 98
Metastatic Breast Cancer - Pipeline by Galileo Research s.r.l., H1 2015 99
Metastatic Breast Cancer - Pipeline by Genentech, Inc., H1 2015 100
Metastatic Breast Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2015 101
Metastatic Breast Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015 102
Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H1 2015 103
Metastatic Breast Cancer - Pipeline by GTx, Inc., H1 2015 104
Metastatic Breast Cancer - Pipeline by Hospira, Inc., H1 2015 105
Metastatic Breast Cancer - Pipeline by Immune Design Corp., H1 2015 106
Metastatic Breast Cancer - Pipeline by Immunomedics, Inc., H1 2015 107
Metastatic Breast Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2015 108
Metastatic Breast Cancer - Pipeline by Immupharma Plc, H1 2015 109
Metastatic Breast Cancer - Pipeline by Imugene Limited, H1 2015 110
Metastatic Breast Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 111
Metastatic Breast Cancer - Pipeline by Incyte Corporation, H1 2015 112
Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 113
Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 114
Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H1 2015 115
Metastatic Breast Cancer - Pipeline by Kadmon Corporation, LLC, H1 2015 116
Metastatic Breast Cancer - Pipeline by Kancera AB, H1 2015 117
Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 118
Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 119
Metastatic Breast Cancer - Pipeline by Mabion SA, H1 2015 120
Metastatic Breast Cancer - Pipeline by MacroGenics, Inc., H1 2015 121
Metastatic Breast Cancer - Pipeline by MandalMed, Inc., H1 2015 122
Metastatic Breast Cancer - Pipeline by Meabco A/S, H1 2015 123
Metastatic Breast Cancer - Pipeline by MedImmune, LLC, H1 2015 124
Metastatic Breast Cancer - Pipeline by Merck & Co., Inc., H1 2015 125
Metastatic Breast Cancer - Pipeline by Merck KGaA, H1 2015 126
Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 127
Metastatic Breast Cancer - Pipeline by Merus B.V., H1 2015 128
Metastatic Breast Cancer - Pipeline by MetaStat, Inc., H1 2015 129
Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 130
Metastatic Breast Cancer - Pipeline by Morphotek, Inc., H1 2015 131
Metastatic Breast Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2015 132
Metastatic Breast Cancer - Pipeline by Natco Pharma Limited, H1 2015 133
Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H1 2015 134
Metastatic Breast Cancer - Pipeline by NewLink Genetics Corporation, H1 2015 135
Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2015 136
Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2015 137
Metastatic Breast Cancer - Pipeline by Novartis AG, H1 2015 138
Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2015 139
Metastatic Breast Cancer - Pipeline by OBI Pharma, Inc., H1 2015 140
Metastatic Breast Cancer - Pipeline by Oncobiologics, Inc., H1 2015 141
Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 142
Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 143
Metastatic Breast Cancer - Pipeline by Oncothyreon Inc., H1 2015 144
Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 145
Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 146
Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015 147
Metastatic Breast Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 148
Metastatic Breast Cancer - Pipeline by Pfizer Inc., H1 2015 149
Metastatic Breast Cancer - Pipeline by Pharma Mar, S.A., H1 2015 150
Metastatic Breast Cancer - Pipeline by Plexxikon Inc., H1 2015 151
Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 152
Metastatic Breast Cancer - Pipeline by Polyphor Ltd., H1 2015 153
Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd., H1 2015 154
Metastatic Breast Cancer - Pipeline by Puma Biotechnology, Inc., H1 2015 155
Metastatic Breast Cancer - Pipeline by Radius Health, Inc., H1 2015 156
Metastatic Breast Cancer - Pipeline by Samyang Holdings Corporation, H1 2015 157
Metastatic Breast Cancer - Pipeline by Seattle Genetics, Inc., H1 2015 158
Metastatic Breast Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2015 159
Metastatic Breast Cancer - Pipeline by Starpharma Holdings Limited, H1 2015 160
Metastatic Breast Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 161
Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 162
Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 163
Metastatic Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 164
Metastatic Breast Cancer - Pipeline by Theracrine, Inc., H1 2015 165
Metastatic Breast Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2015 166
Metastatic Breast Cancer - Pipeline by Transgene Biotek Limited, H1 2015 167
Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2015 168
Metastatic Breast Cancer - Pipeline by Verastem, Inc., H1 2015 169
Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 170
Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H1 2015 171
Metastatic Breast Cancer - Pipeline by Wilex AG, H1 2015 172
Metastatic Breast Cancer - Pipeline by WntResearch AB, H1 2015 173
Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2015 174
Metastatic Breast Cancer - Pipeline by Zymeworks Inc., H1 2015 175
Metastatic Breast Cancer - Pipeline by Zyngenia, Inc., H1 2015 176
Assessment by Monotherapy Products, H1 2015 177
Assessment by Combination Products, H1 2015 178
Number of Products by Stage and Target, H1 2015 180
Number of Products by Stage and Mechanism of Action, H1 2015 191
Number of Products by Stage and Route of Administration, H1 2015 199
Number of Products by Stage and Molecule Type, H1 2015 201
Metastatic Breast Cancer Therapeutics - Recent Pipeline Updates, H1 2015 603
Metastatic Breast Cancer - Dormant Projects, H1 2015 839
Metastatic Breast Cancer - Dormant Projects (Contd..1), H1 2015 840
Metastatic Breast Cancer - Dormant Projects (Contd..2), H1 2015 841
Metastatic Breast Cancer - Dormant Projects (Contd..3), H1 2015 842
Metastatic Breast Cancer - Dormant Projects (Contd..4), H1 2015 843
Metastatic Breast Cancer - Dormant Projects (Contd..5), H1 2015 844
Metastatic Breast Cancer - Dormant Projects (Contd..6), H1 2015 845
Metastatic Breast Cancer - Dormant Projects (Contd..7), H1 2015 846
Metastatic Breast Cancer - Dormant Projects (Contd..8), H1 2015 847
Metastatic Breast Cancer - Dormant Projects (Contd..9), H1 2015 848
Metastatic Breast Cancer - Dormant Projects (Contd..10), H1 2015 849
Metastatic Breast Cancer - Discontinued Products, H1 2015 850
Metastatic Breast Cancer - Discontinued Products (Contd..1), H1 2015 851
Metastatic Breast Cancer - Discontinued Products (Contd..2), H1 2015 852
Metastatic Breast Cancer - Discontinued Products (Contd..3), H1 2015 853
Metastatic Breast Cancer - Discontinued Products (Contd..4), H1 2015 854

List of Figures
Number of Products under Development for Metastatic Breast Cancer, H1 2015 31
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2015 32
Number of Products under Development by Companies, H1 2015 33
Number of Products under Investigation by Universities/Institutes, H1 2015 43
Comparative Analysis by Late Stage Development, H1 2015 45
Comparative Analysis by Clinical Stage Development, H1 2015 46
Comparative Analysis by Early Stage Products, H1 2015 47
Assessment by Monotherapy Products, H1 2015 177
Assessment by Combination Products, H1 2015 178
Number of Products by Top 10 Targets, H1 2015 179
Number of Products by Stage and Top 10 Targets, H1 2015 179
Number of Products by Top 10 Mechanism of Actions, H1 2015 190
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 190
Number of Products by Top 10 Routes of Administration, H1 2015 198
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 198
Number of Products by Top 10 Molecule Types, H1 2015 200
Number of Products by Stage and Top 10 Molecule Types, H1 2015 200

NA

NA